Painful pullback on PRED , but it was well needed if we want higher prices longer term .
https://seekingalpha.com/instablog/...Fn7Vur0nZG9N4D_WZFzDhfWM55TUwNdapSaDVaFE5Bd8o
https://seekingalpha.com/instablog/...Fn7Vur0nZG9N4D_WZFzDhfWM55TUwNdapSaDVaFE5Bd8o
hno:PRED PULLED BACK TO A SUPPORT AREA , NO WORRIES YET, SHOULD SETTLE AND BOUNCE HERE
| [SIZE=-1]Printer friendly charts[/SIZE] |
|
|
RAFA
Summary & Recommendation
Rafarma is an international biotechnological and pharmaceutical
company that combines research centers and modern pharmaceutical
production which meet international GMP standards. The multi-
product pharmaceutical company produces and sells APIs, drugs,
generic antibiotics, vaccines and specialty pharma products in Europe
& Asia. The company has embarked on an aggressive plan of global
partnerships with over 200 companies. Valuation is attractive relative
to peers; therefore we initiate on RAFA at BUY with $12 price
target.
Price target raised - management had meetings with some very
wealthy investors and based on feedback we receved we are raising
the price target to $16.
July 2021 IG EQUITY RESEARCH REPORT.pdf - Google Drive
Summary & Recommendation
Rafarma is an international biotechnological and pharmaceutical
company that combines research centers and modern pharmaceutical
production which meet international GMP standards. The multi-
product pharmaceutical company produces and sells APIs, drugs,
generic antibiotics, vaccines and specialty pharma products in Europe
& Asia. The company has embarked on an aggressive plan of global
partnerships with over 200 companies. Valuation is attractive relative
to peers; therefore we initiate on RAFA at BUY with $12 price
target.
Price target raised - management had meetings with some very
wealthy investors and based on feedback we receved we are raising
the price target to $16.
July 2021 IG EQUITY RESEARCH REPORT.pdf - Google Drive
[FONT="]Nicosia, Cyprus, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC: (RAFA) shares the following letter to shareholders from Chairman of the Board Ilya Shpurov:[/FONT]
[FONT="]“It is my pleasure to provide the following update on the exciting future and status of Rafarma's audit.[/FONT]
[FONT="]The company intends to file Form a 10 with the SEC to initiate SEC reporting status. In order for this to happen, we must complete our previously announced audit. The audit has challenges which have affected the timeline.[/FONT]
[FONT="]A significant number of the company's industrial assets are located in Russia, where the deadline for submitting the annual reports of public companies according to the international standard is July 15th. We have to audit them and convert them to GAAP, which is happening right now. We are currently working with several audit firms including Soldinger & Associates to obtain a PCAOB audit of the financial performance of Rafarma Pharmaceuticals Inc. in accordance with GAAP.[/FONT]
[FONT="]As a CEO, I have been involved in many transactions around the world and understand the concerns of shareholders about a company's assets. We have not previously conducted a PCAOB audit for any of our companies, and we are working through the learning curve with a goal of maximum transparency.[/FONT]
[FONT="]However, I feel confident that we are close to completing the audit. We expect its completion in the next 6-8 weeks. This audit includes consolidated reports from several large companies in various jurisdictions. This was a very big undertaking for our company and we are delighted to complete this process and move on to the next steps in our plans for the company.[/FONT]
[FONT="]I am also pleased to announce that the company recently signed a number of agreements to develop new drugs in the treatment of behavioral disorders, which will be announced later.”[/FONT]
[FONT="]Forward-looking statements:[/FONT]
[FONT="]“It is my pleasure to provide the following update on the exciting future and status of Rafarma's audit.[/FONT]
[FONT="]The company intends to file Form a 10 with the SEC to initiate SEC reporting status. In order for this to happen, we must complete our previously announced audit. The audit has challenges which have affected the timeline.[/FONT]
[FONT="]A significant number of the company's industrial assets are located in Russia, where the deadline for submitting the annual reports of public companies according to the international standard is July 15th. We have to audit them and convert them to GAAP, which is happening right now. We are currently working with several audit firms including Soldinger & Associates to obtain a PCAOB audit of the financial performance of Rafarma Pharmaceuticals Inc. in accordance with GAAP.[/FONT]
[FONT="]As a CEO, I have been involved in many transactions around the world and understand the concerns of shareholders about a company's assets. We have not previously conducted a PCAOB audit for any of our companies, and we are working through the learning curve with a goal of maximum transparency.[/FONT]
[FONT="]However, I feel confident that we are close to completing the audit. We expect its completion in the next 6-8 weeks. This audit includes consolidated reports from several large companies in various jurisdictions. This was a very big undertaking for our company and we are delighted to complete this process and move on to the next steps in our plans for the company.[/FONT]
[FONT="]I am also pleased to announce that the company recently signed a number of agreements to develop new drugs in the treatment of behavioral disorders, which will be announced later.”[/FONT]
[FONT="]Forward-looking statements:[/FONT]
https://sec.report/otc/financial-report/297500
$RAFA 2nd Quarter Results [Unaudited]
sec.report/otc/financial-…
*HIGHLIGHTS*
> $34,101,000 Sales Revenue
> $12,700,000 Gross Profit
> $5,090,000 Net Income
> $0.058 Net Income / per share
> $11,275,000 Cash on Hand
> Shares Outstanding 87,766,999
$RAFA 2nd Quarter Results [Unaudited]
sec.report/otc/financial-…
*HIGHLIGHTS*
> $34,101,000 Sales Revenue
> $12,700,000 Gross Profit
> $5,090,000 Net Income
> $0.058 Net Income / per share
> $11,275,000 Cash on Hand
> Shares Outstanding 87,766,999
Charts improving on PRED, and Rafa
Stock Technical Analysis: Analysis of PRED based on EMA, MACD, RSI, Stochastic, Fibonacci, trends and gaps (stockta.com) back over its long term mvg avg
Stock Technical Analysis: Analysis of RAFA based on EMA, MACD, RSI, Stochastic, Fibonacci, trends and gaps (stockta.com) breaking its downtrend, and testing its int term mvg avg
Stock Technical Analysis: Analysis of PRED based on EMA, MACD, RSI, Stochastic, Fibonacci, trends and gaps (stockta.com) back over its long term mvg avg
Stock Technical Analysis: Analysis of RAFA based on EMA, MACD, RSI, Stochastic, Fibonacci, trends and gaps (stockta.com) breaking its downtrend, and testing its int term mvg avg
SAA ADV .
PREDICTIVE TECHNOLOGY GROUP, INC (PRED~.10)
Final note: PRED has been a dog and hurtful to shareholders for a long time, but we have not lost hope.
We see on their website (www.predtechgroup.com) within their Biotech division the introduction of a "new" product, AmnioBind~ Advanced placental wound covering! (listed on website November 1, 2021)
AmnioBind, is a dehydrated, intact placental membrane that preserves the naturally occurring cytokines, growth factors, comprehensive collagen matrix, glycoconjugates, and glycosaminoglycans. It is derived from the placental membranes from donated, full-term birth tissue. PRED has a process that maintains the tissue's biological components with minimal degradation of native proteins.
Within the Predictive Biotech sub please review
www.predictivebiotech.com/products/ and review the complete and current report by "clicking" the "AmnioBind characterization report highlighted in BLUE!
The Global Wound Care Market size was valued at $20 billion in 2019 and is anticipated to reach $28 billion by 2027. The total U.S. market for wound care anticipated to reach $15 billion by 2025.
Technological advancement in wound care leads the industry. Maybe PRED can pull another rabbit out their hat! According to my memory they were issued a patent on this development a number of months ago.
Recently PRED was issued another patent that could be valuable for the treatment of scoliosis (issued June 1, 2021) The global scoliosis management market size was estimated to be $2.6 billion and is anticipated to reach $3.9 billion by 2031.
We understand there has been missteps and missed opportunities concerning PRED. Some issues the company could not have foreseen, such as, Covid and the FDA limiting the use of HCT/P for medical ailments. It is not over for PRED and patience is the only ingredient that one must depend upon.
(Note: Hemacare (hema) was recommended after the stock fell from $3 to .25 only to be bought out @ $25.00 a few years later.)
PREDICTIVE TECHNOLOGY GROUP, INC (PRED~.10)
Final note: PRED has been a dog and hurtful to shareholders for a long time, but we have not lost hope.
We see on their website (www.predtechgroup.com) within their Biotech division the introduction of a "new" product, AmnioBind~ Advanced placental wound covering! (listed on website November 1, 2021)
AmnioBind, is a dehydrated, intact placental membrane that preserves the naturally occurring cytokines, growth factors, comprehensive collagen matrix, glycoconjugates, and glycosaminoglycans. It is derived from the placental membranes from donated, full-term birth tissue. PRED has a process that maintains the tissue's biological components with minimal degradation of native proteins.
Within the Predictive Biotech sub please review
www.predictivebiotech.com/products/ and review the complete and current report by "clicking" the "AmnioBind characterization report highlighted in BLUE!
The Global Wound Care Market size was valued at $20 billion in 2019 and is anticipated to reach $28 billion by 2027. The total U.S. market for wound care anticipated to reach $15 billion by 2025.
Technological advancement in wound care leads the industry. Maybe PRED can pull another rabbit out their hat! According to my memory they were issued a patent on this development a number of months ago.
Recently PRED was issued another patent that could be valuable for the treatment of scoliosis (issued June 1, 2021) The global scoliosis management market size was estimated to be $2.6 billion and is anticipated to reach $3.9 billion by 2031.
We understand there has been missteps and missed opportunities concerning PRED. Some issues the company could not have foreseen, such as, Covid and the FDA limiting the use of HCT/P for medical ailments. It is not over for PRED and patience is the only ingredient that one must depend upon.
(Note: Hemacare (hema) was recommended after the stock fell from $3 to .25 only to be bought out @ $25.00 a few years later.)
